Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
Eli Lilly & Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical firm focused on the discovery of novel medications for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to inhibit activin and myostatin signaling. Bimagrumab is currently being tested in individuals who are overweight or obese in the BELIEVE Phase IIb research, both alone and in combination with semaglutide. Combining incretins with bimagrumab...